Although the company will continue to pursue « higher-risk, high reward » drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky. As detailed by Sportsmail last week, the FA were understood to have pointed Public Health England to the precedent of socially-distanced training […]